Community Acquired Pneumonia - Pipeline Review, H1 2014

Community Acquired Pneumonia - Pipeline Review, H1 2014

Summary

Global Markets Direct’s, ‘Community Acquired Pneumonia - Pipeline Review, H1 2014’, provides an overview of the Community Acquired Pneumonia’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Community Acquired Pneumonia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Community Acquired Pneumonia and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Community Acquired Pneumonia
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Community Acquired Pneumonia and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Community Acquired Pneumonia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Community Acquired Pneumonia pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Community Acquired Pneumonia
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Community Acquired Pneumonia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Community Acquired Pneumonia Overview 7
Therapeutics Development 8
Pipeline Products for Community Acquired Pneumonia - Overview 8
Pipeline Products for Community Acquired Pneumonia - Comparative Analysis 9
Community Acquired Pneumonia - Therapeutics under Development by Companies 10
Community Acquired Pneumonia - Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Community Acquired Pneumonia - Products under Development by Companies 15
Community Acquired Pneumonia - Companies Involved in Therapeutics Development 16
AstraZeneca PLC 16
Biotest AG 17
Paratek Pharmaceuticals, Inc. 18
Basilea Pharmaceutica AG 19
Kyorin Pharmaceutical Co., Ltd. 20
TaiGen Biotechnology Co., Ltd. 21
C10 Pharma AS 22
Community Acquired Pneumonia - Therapeutics Assessment 23
Assessment by Monotherapy Products 23
Assessment by Combination Products 24
Assessment by Target 25
Assessment by Mechanism of Action 28
Assessment by Route of Administration 30
Assessment by Molecule Type 32
Drug Profiles 34
ceftobiprole medocaril - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
nemonoxacin - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
ticagrelor - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
omadacycline tosylate - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
nemonoxacin - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
BT-086 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
(eptifibatide + iloprost) - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
KRPAM-1977X - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
Small Molecules for Skin and Soft Tissue and Community Acquired Pneumonia Infections - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
C-10 - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
Community Acquired Pneumonia - Recent Pipeline Updates 55
Community Acquired Pneumonia - Dormant Projects 65
Community Acquired Pneumonia - Discontinued Products 66
Community Acquired Pneumonia - Product Development Milestones 67
Featured News & Press Releases 67
Sep 11, 2013: New Antibiotic Shows Promise for Treating MRSA Pneumonia 67
May 16, 2013: TaiGen Biotechnology Submits New Drug Application For Nemonoxacin In Taiwan And China 67
Oct 17, 2012: Cempra Continues To Differentiate Solithromycin's Potency And Activity Compared To Other Macrolides In Presentations At IDWeek 2012 68
Oct 10, 2012: Rib-X Pharma Receives Qualified Infectious Disease Product Designation From FDA For Radezolid 69
Sep 17, 2012: Rib-X Pharma Receives Qualified Infectious Disease Product Designation From FDA For Delafloxacin 70
Sep 11, 2012: Rib-X Pharma Presents Data From Multiple Radezolid Studies At ICAAC 2012 71
Aug 28, 2012: European Commission Approves Zinforo To Treat Skin Infections Or Community Acquired Pneumonia 72
Jul 30, 2012: Basilea Pharma Submits European Marketing Authorization Application Of Ceftobiprole For Treatment Of Pneumonia 72
Jun 22, 2012: CHPM Adopts Positive Opinion For Zinforo For Treatment Of Complicated Skin And Soft Tissue Infections 73
Apr 08, 2010: First clinical study expected to start September 2010 74
Appendix 75
Methodology 75
Coverage 75
Secondary Research 75
Primary Research 75
Expert Panel Validation 75
Contact Us 76
Disclaimer 76

List of Tables
Number of Products under Development for Community Acquired Pneumonia, H1 2014 8
Number of Products under Development for Community Acquired Pneumonia - Comparative Analysis, H1 2014 9
Number of Products under Development by Companies, H1 2014 11
Comparative Analysis by Late Stage Development, H1 2014 12
Comparative Analysis by Clinical Stage Development, H1 2014 13
Comparative Analysis by Early Stage Development, H1 2014 14
Products under Development by Companies, H1 2014 15
Community Acquired Pneumonia - Pipeline by AstraZeneca PLC, H1 2014 16
Community Acquired Pneumonia - Pipeline by Biotest AG, H1 2014 17
Community Acquired Pneumonia - Pipeline by Paratek Pharmaceuticals, Inc., H1 2014 18
Community Acquired Pneumonia - Pipeline by Basilea Pharmaceutica AG, H1 2014 19
Community Acquired Pneumonia - Pipeline by Kyorin Pharmaceutical Co., Ltd., H1 2014 20
Community Acquired Pneumonia - Pipeline by TaiGen Biotechnology Co., Ltd., H1 2014 21
Community Acquired Pneumonia - Pipeline by C10 Pharma AS, H1 2014 22
Assessment by Monotherapy Products, H1 2014 23
Assessment by Combination Products, H1 2014 24
Number of Products by Stage and Target, H1 2014 27
Number of Products by Stage and Mechanism of Action, H1 2014 29
Number of Products by Stage and Route of Administration, H1 2014 31
Number of Products by Stage and Molecule Type, H1 2014 33
Community Acquired Pneumonia Therapeutics - Recent Pipeline Updates, H1 2014 55
Community Acquired Pneumonia - Dormant Projects, H1 2014 65
Community Acquired Pneumonia - Discontinued Products, H1 2014 66

List of Figures
Number of Products under Development for Community Acquired Pneumonia, H1 2014 8
Number of Products under Development for Community Acquired Pneumonia - Comparative Analysis, H1 2014 9
Number of Products under Development by Companies, H1 2014 10
Comparative Analysis by Early Stage Products, H1 2014 14
Assessment by Monotherapy Products, H1 2014 23
Number of Products by Top 10 Target, H1 2014 25
Number of Products by Stage and Top 10 Target, H1 2014 26
Number of Products by Top 10 Mechanism of Action, H1 2014 28
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 29
Number of Products by Top 10 Route of Administration, H1 2014 30
Number of Products by Stage and Top 10 Route of Administration, H1 2014 31
Number of Products by Top 10 Molecule Type, H1 2014 32
Number of Products by Stage and Top 10 Molecule Type, H1 2014 33